Nasdaq:ACLS
AXCELIS TECHNOLOGIES INC
A leading US-based innovator of advanced medical imaging systems including CT scanners and interventional X-ray solutions for hospitals and surgery centers.
Key Metrics
Investment Thesis
Bull Case
ACLS offers a compelling value play for investors seeking exposure to the secular growth of medical imaging without paying a premium for a large-cap monopoly. The company's ability to generate strong free cash flow allows it to return capital to shareholders through buybacks while continuing to invest in R&D, potentially accelerating growth once market conditions stabilize. Its niche focus on radiation therapy and advanced CT technology positions it well to capture share from competitors facing slower innovation cycles.
Bear Case
The significant revenue contraction seen in 2024 and 2025 indicates a vulnerable business model that may be struggling with cyclicality or intense competitive pressure. A large retained earnings deficit of $503.5M combined with high operating expenses suggests the company is burning through historical capital to sustain operations during this downturn. If market demand does not recover quickly, the company's limited product portfolio and lack of diversification could prevent it from regaining its previous growth trajectory.
About AXCELIS TECHNOLOGIES INC
AXCELIS Technologies (ACLS) designs and manufactures advanced medical imaging systems including CT scanners and interventional X-ray solutions primarily for the North American market. The company serves hospitals, ambulatory surgery centers, and imaging practices by providing high-performance diagnostic equipment that enhances clinical workflow and patient care. With a strong focus on innovation in radiation therapy and digital imaging, ACLS competes against major global players to deliver next-generation medical technology.
Analysis
Management Discussion
Despite a significant year-over-year revenue decline from 2023 levels, the company maintained robust profitability with net income of $120.2M on $839.0M in revenue. Strong operating cash flow of $118.3M and a healthy balance sheet with $145.5M in cash provide flexibility for capital expenditures of $11.3M and substantial share repurchases of $121.1M, signaling management confidence in the business model. However, the sharp contraction in revenue suggests potential headwinds in market demand or pricing dynamics that warrant close monitoring.
Industry Overview
The global medical imaging market is expanding as hospitals upgrade aging equipment and demand for early cancer detection rises, favoring manufacturers with advanced digital technologies. Regulatory environments are tightening around radiation safety and cybersecurity, creating barriers to entry that protect established players but require continuous compliance investment. Consolidation is common in this sector, yet niche specialists who offer superior service models and proprietary software platforms can carve out sustainable market positions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $920.0M | $1.13B | $1.02B | $839.0M |
| Cost of Revenue | $518.2M | $639.3M | $563.2M | $462.2M |
| Gross Profit | $401.8M | $491.3M | $454.7M | $376.8M |
| Operating Expenses | $189.4M | $225.5M | $243.9M | $257.5M |
| Operating Income | $212.4M | $265.8M | $210.8M | $119.3M |
| R&D | $78.4M | $96.9M | $105.5M | $109.0M |
| G&A | $57.5M | $65.8M | $70.3M | $83.2M |
| Marketing | $53.6M | $62.8M | $68.0M | $65.4M |
| Stock-Based Comp | $13.4M | $18.3M | $21.0M | $20.8M |
| D&A | $11.6M | $13.1M | $15.8M | $17.6M |
| Depreciation | $5.1M | $6.2M | $7.7M | $8.7M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $-7.5M | $12.8M | $19.5M | $18.9M |
| Interest Expense | $5.6M | $5.3M | — | — |
| Interest Income | $4.6M | $18.2M | $24.4M | $21.5M |
| Pre-Tax Income | $204.9M | $278.6M | $230.3M | $138.2M |
| Income Tax | $21.8M | $32.3M | $29.3M | $18.0M |
| Continuing Ops | $183.1M | $246.3M | $201.0M | $120.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $183.1M | $246.3M | $201.0M | $120.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $183.1M | $246.3M | $201.0M | $120.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $877.6M | $1.08B | $1.12B | $943.2M |
| Cash & Equivalents | $185.6M | $167.3M | $123.5M | $145.5M |
| Marketable Securities | $246.6M | $338.9M | $447.8M | $228.8M |
| Accounts Receivable | $169.8M | $218.0M | $203.1M | $168.5M |
| Inventory | $242.4M | $306.5M | $282.2M | $329.0M |
| Prepaid Expenses | $33.3M | $49.4M | $60.5M | $66.8M |
| Other Current Assets | $0 | $0 | $6.4M | $4.7M |
| Long-Term Assets | $136.0M | $202.0M | $225.2M | $418.1M |
| PP&E (Net) | $39.7M | $54.0M | $53.8M | $56.1M |
| Operating Leases | $12.1M | $30.7M | $29.6M | $28.9M |
| Other LT Assets | $84.2M | $117.3M | $141.8M | $333.1M |
| Total Assets | $1.01B | $1.28B | $1.35B | $1.36B |
| Current Liabilities | $248.1M | $285.1M | $207.5M | $197.7M |
| Accounts Payable | $62.3M | $54.4M | $46.9M | $42.3M |
| Current Leases | $5.4M | $5.0M | $4.5M | $4.9M |
| Deferred Revenue | $123.5M | $164.7M | $94.7M | $65.5M |
| Taxes Payable | $4.3M | $6.2M | — | $11.4M |
| Other Current Liab | $52.6M | $54.9M | $61.5M | $73.6M |
| Long-Term Liabilities | $98.3M | $132.0M | $128.5M | $129.0M |
| LT Operating Leases | $6.9M | $25.7M | $25.3M | $24.6M |
| Other LT Liab | $60.0M | $60.0M | $59.6M | $61.0M |
| Total Liabilities | $346.4M | $417.1M | $336.0M | $326.7M |
| Shareholders' Equity | $667.3M | $864.9M | $1.01B | $1.03B |
| Paid-In Capital | $550.3M | $547.2M | $548.7M | $533.3M |
| Retained Earnings | $118.9M | $319.5M | $470.3M | $503.5M |
| AOCI | $-2.0M | $-1.8M | $-6.2M | $-2.2M |
| Total L&E | $1.01B | $1.28B | $1.35B | $1.36B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $183.1M | $246.3M | $201.0M | $120.2M |
| Non-Cash Adjustments | $-221.6M | $-290.4M | $15.5M | $-12.1M |
| Working Capital Changes | $254.1M | $201.0M | $-75.7M | $10.2M |
| Cash from Operations | $215.6M | $156.9M | $140.8M | $118.3M |
| Capital Expenditures | $10.7M | $20.7M | $12.2M | $11.3M |
| Cash from Investing | $-257.3M | $-100.9M | $-108.7M | $29.9M |
| Share Buybacks | $57.5M | $52.5M | $60.5M | $121.1M |
| Cash from Financing | $-65.5M | $-68.3M | $-71.2M | $-124.5M |
| FX Effect | $-2.2M | $-139.0K | $-3.8M | $1.3M |
| Net Change in Cash | $-109.3M | $-12.4M | $-42.9M | $25.0M |
| Beginning Cash | $295.7M | $186.3M | $174.0M | $131.1M |
| Ending Cash | $186.3M | $174.0M | $131.1M | $156.1M |
Frequently Asked Questions
How does AXCELIS TECHNOLOGIES INC make money?
The company's revenue is driven by the sale and service of high-end CT scanners, interventional fluoroscopy systems, and radiation therapy equipment. Additional revenue streams include after-market services, spare parts, and software upgrades that support existing medical imaging infrastructure. The business also generates income from international sales, though a significant portion of revenue originates from domestic US healthcare facilities.
What are the main risks for ACLS?
Intense competition from established giants like Siemens Healthineers, GE Healthcare, and Canon Medical could lead to pricing pressure or market share erosion in the CT scanner segment. Dependence on a concentrated geographic market, particularly the United States, exposes the company to regional healthcare spending cuts, regulatory changes, and reimbursement policy shifts. Supply chain disruptions for specialized electronic components and rare earth materials used in imaging detectors could delay product launches or increase manufacturing costs.
What is ACLS's competitive advantage?
ACLS leverages its deep expertise in radiation physics and engineering to develop proprietary image reconstruction algorithms that provide superior diagnostic quality at lower radiation doses. The company maintains a nimble product development cycle allowing rapid iteration on hardware and software features compared to larger, slower-moving competitors. A dedicated US-based service network ensures quick response times for hospital clients, fostering strong customer retention and recurring service revenue.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.